Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

2.

Bisphosphonates and other bone agents for breast cancer.

Wong MH, Stockler MR, Pavlakis N.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD003474. doi: 10.1002/14651858.CD003474.pub3. Review.

PMID:
22336790
3.

Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors.

Brown-Glaberman U, Stopeck AT.

Biologics. 2012;6:89-99. doi: 10.2147/BTT.S20677. Epub 2012 Apr 12.

4.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
5.

Bisphosphonates for breast cancer.

Pavlakis N, Stockler M.

Cochrane Database Syst Rev. 2002;(1):CD003474. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003474.

PMID:
11869664
6.

Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.

Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S.

J Clin Oncol. 2007 Oct 1;25(28):4431-7. Epub 2007 Sep 4.

PMID:
17785705
7.

Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion.

Steger GG, Bartsch R.

Ther Adv Med Oncol. 2011 Sep;3(5):233-43. doi: 10.1177/1758834011412656.

8.

Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials.

Chen F, Pu F.

Oncol Res Treat. 2016;39(7-8):453-9. doi: 10.1159/000447372. Epub 2016 Jun 29. Review.

PMID:
27487236
9.

Denosumab: in the prevention of skeletal-related events in patients with bone metastases from solid tumours.

Scott LJ, Muir VJ.

Drugs. 2011 May 28;71(8):1059-69. doi: 10.2165/11207370-000000000-00000. Review.

PMID:
21668042
10.

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S.

J Clin Oncol. 2009 Apr 1;27(10):1564-71. doi: 10.1200/JCO.2008.19.2146. Epub 2009 Feb 23.

PMID:
19237632
11.

Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art.

Clemons M, Gelmon KA, Pritchard KI, Paterson AH.

Curr Oncol. 2012 Oct;19(5):259-68. doi: 10.3747/co.19.1011.

12.

Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours.

Ford J, Cummins E, Sharma P, Elders A, Stewart F, Johnston R, Royle P, Jones R, Mulatero C, Todd R, Mowatt G.

Health Technol Assess. 2013 Jul;17(29):1-386. doi: 10.3310/hta17290. Review.

13.

Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.

Gartrell BA, Coleman RE, Fizazi K, Miller K, Saad F, Sternberg CN, Galsky MD.

Eur Urol. 2014 Feb;65(2):278-86. doi: 10.1016/j.eururo.2013.05.015. Epub 2013 May 13. Review.

14.

Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice.

Li BT, Wong MH, Pavlakis N.

J Clin Med. 2014 Jan 9;3(1):1-24. doi: 10.3390/jcm3010001. Review.

15.

[The treatment for cancer with bone metastases -whether to use zoledoronate or denosumab for bone metastases-].

Kohno N.

Clin Calcium. 2014 Aug;24(8):1229-36. doi: CliCa140812291236. Review. Japanese.

PMID:
25065876
16.

Bisphosphonates for cancer patients: why, how, and when?

Body JJ, Mancini I.

Support Care Cancer. 2002 Jul;10(5):399-407. Epub 2001 Oct 19. Review.

PMID:
12136223
17.

Management of bone metastases in refractory prostate cancer--role of denosumab.

Paller CJ, Carducci MA, Philips GK.

Clin Interv Aging. 2012;7:363-72. doi: 10.2147/CIA.S27930. Epub 2012 Sep 17. Review.

18.

Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.

Iranikhah M, Wilborn TW, Wensel TM, Ferrell JB.

Pharmacotherapy. 2012 Mar;32(3):274-84. doi: 10.1002/j.1875-9114.2011.01092.x. Epub 2012 Feb 13. Review.

PMID:
22392458
19.

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S.

Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10.

PMID:
22975218
20.

Efficacy and safety of denosumab for the treatment of bone metastases in patients with advanced cancer.

Kurata T, Nakagawa K.

Jpn J Clin Oncol. 2012 Aug;42(8):663-9. doi: 10.1093/jjco/hys088. Epub 2012 Jun 13. Review.

PMID:
22701037

Supplemental Content

Support Center